Acyclovir
- Generic Name
- Acyclovir
- Brand Names
- Sitavig, Xerese, Zovirax
- Drug Type
- Small Molecule
- Chemical Formula
- C8H11N5O3
- CAS Number
- 59277-89-3
- Unique Ingredient Identifier
- X4HES1O11F
- Background
Acyclovir is a nucleotide analog antiviral used to treat herpes simplex, Varicella zoster, herpes zoster, herpes labialis, and acute herpetic keratitis. Acyclovir is generally used first line in the treatment of these viruses and some products are indicated for patients as young as 6 years old.
Acyclovir was granted FDA approval on 29 March 1982.
- Indication
An acyclovir topical cream is indicated to treat recurrent herpes labialis in immunocompetent patients 12 years and older. Acyclovir oral tablets, capsules, and suspensions are indicated to treat herpes zoster, genital herpes, and chickenpox. An acyclovir topical ointment is indicated to treat initial genital herpes and limited non-life-threatening mucocutan...
- Associated Conditions
- Bell's Palsy, Chickenpox, Cytomegalovirus (CMV) Infections, Herpes Simplex Infections, Herpes Zoster, Herpes simplex encephalitis, Herpes simplex of the oral-labial, Herpes simplex type I reactivation, Recurrent Genital Herpes (RGH), Recurrent Herpes Labialis, VZV re-activation, Acute Genital herpes, Acute Herpes labialis, Acute Herpetic keratitis, Severe Genital herpes
- Associated Therapies
- -
A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 20
- Registration Number
- NCT02977533
- Locations
- 🇩🇪
Investigational Site Number 276001, Berlin, Germany
A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 24
- Registration Number
- NCT02583594
- Locations
- 🇪🇸
Investigational Site Number 724001, Barcelona, Spain
Antiviral Prophylaxis in a Burn Population
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Southern Illinois University
- Registration Number
- NCT02349828
- Locations
- 🇺🇸
Southern Illinois University School of Medicine, Springfield, Illinois, United States
Aseptic Meningoencephalitis in Slovenia
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 800
- Registration Number
- NCT02328469
- Locations
- 🇸🇮
UMC Ljubljana, Department of Infectious Diseases, Ljubljana, Slovenia
🇸🇮Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia
A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 48
- Registration Number
- NCT02282826
- Locations
- 🇩🇪
Investigational Site Number 276001, Berlin, Germany
Bioequivalence of Two Formulations of Acyclovir
- First Posted Date
- 2014-10-03
- Last Posted Date
- 2014-10-03
- Lead Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT02255734
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA
- First Posted Date
- 2014-07-31
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 58
- Registration Number
- NCT02205489
- Locations
- 🇧🇪
Investigational Site Number 056001, Brussels, Belgium
🇳🇱Investigational Site Number 528001, Breda, Netherlands
🇳🇱Investigational Site Number 528002, Rotterdam, Netherlands
PTH - Preemptive Treatment for Herpesviridae
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Target Recruit Count
- 317
- Registration Number
- NCT02152358
- Locations
- 🇫🇷
Assistance Publique - Hôpitaux de Marseille, Marseille, France
Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Cttq
- Target Recruit Count
- 94
- Registration Number
- NCT02151240
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT02073097
- Locations
- 🇺🇸
Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.